- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Cardiovascular safety trial of sitagliptin met primary endpoint in patients with type 2 diabetes
30 June 2015 • Author: Victoria White
MSD recently announced the primary results of the TECOS trial, a placebo-controlled study of the cardiovascular (CV) safety of MSD’s DPP-4 inhibitor, Januvia (sitagliptin).
The TECOS cardiovascular safety trial was an event-driven study designed to assess the long-term CV safety of the addition of sitagliptin to usual care, compared to usual care without sitagliptin, in patients with type 2 diabetes and established CV disease. The study enrolled more than 14,735 patients from 38 countries and was led by independent academic research collaboration between the University of Oxford Diabetes Trials Unit and the Duke University Clinical Research Institute, and was sponsored by MSD. Amongst the key findings, it was evident that there was no increase in CV-related deaths or hospitalisation for heart failure in the Sitagliptin group versus placebo.
Sitagliptin did not increase the risk of cardiovascular events
“Patients with type 2 diabetes need antihyperglycaemic medicines to help control their blood sugar. Because these patients are at increased risk for cardiovascular complications, understanding the cardiovascular safety of these medicines is important,” said study co-chair Rury Holman, Professor of Diabetic Medicine and Diabetes Trials Unit Director, University of Oxford. “The results from TECOS showed that sitagliptin did not increase the risk of cardiovascular events in a diverse group of patients with type 2 diabetes at high cardiovascular risk.”
Overall, the primary endpoint occurred in 11.4% of sitagliptin-treated patients compared with 11.6% of placebo-treated patients in the Intention-to-Treat (ITT) analysis, and in 9.6% of patients in both the sitagliptin and placebo groups in the Per Protocol (PP) analysis. In addition, there was no increase in hospitalisation for heart failure, and rates of all-cause mortality were similar in both treatment groups, which were two key secondary endpoints.
“We believe the results of TECOS provide important clinical information about the cardiovascular safety profile of sitagliptin,” said Dr Roger M. Perlmutter, president, Merck Research Laboratories. “The TECOS CV safety trial reflects the best efforts of clinical scientists at the University of Oxford, the Duke Clinical Research Institute and MSD on behalf of patients around the world who suffer from type 2 diabetes.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics